Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts

Senti Biosciences, Inc. (NASDAQ:SNTI) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $9.00.

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of Senti Biosciences to a “sell” rating in a research report on Saturday. Leerink Partners initiated coverage on Senti Biosciences in a report on Friday, November 21st. They issued an “outperform” rating and a $6.00 price target on the stock. Leerink Partnrs raised Senti Biosciences to a “strong-buy” rating in a research report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. Finally, Chardan Capital lifted their price objective on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th.

Institutional Trading of Senti Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Heights Capital Management Inc. acquired a new stake in Senti Biosciences in the 1st quarter valued at about $2,520,000. Armistice Capital LLC purchased a new stake in shares of Senti Biosciences during the second quarter worth $1,883,000. Geode Capital Management LLC raised its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences in the third quarter worth about $117,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Senti Biosciences in the first quarter worth $2,984,000. 25.70% of the stock is owned by institutional investors.

Senti Biosciences Stock Performance

Shares of SNTI opened at $1.21 on Tuesday. The stock has a 50-day moving average of $1.93 and a two-hundred day moving average of $1.92. The stock has a market cap of $31.81 million, a P/E ratio of -0.36 and a beta of 2.08. Senti Biosciences has a one year low of $1.19 and a one year high of $5.44.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). Analysts predict that Senti Biosciences will post -14.54 EPS for the current fiscal year.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.